StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie stock-Based Compensation Expense ($M) ($M)

Form 10-Q / 10-K Consolidated Statements of Cash Flows

QuarterlyAnnual
Latest, Q2 2026
166
Period ended Jun 30, 2026
Change on a year earlier
-7.3%
179 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
37
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedStock-Based Compensation Expense ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026166-7.3%Form 10-Q (filed 2026-08-03) ↗
Q1 2026Mar 31, 2026444+8.3%Form 10-Q (filed 2026-05-08) ↗
Q4 2025Dec 31, 2025157-4.3%Form 10-K (filed 2026-02-20) ↗
Q3 2025Sep 30, 2025209+15.5%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 30, 2025179-17.9%Form 10-Q (filed 2026-08-03) ↗
Q1 2025Mar 31, 2025410+17.8%Form 10-Q (filed 2026-05-08) ↗
Q4 2024Dec 31, 2024164+31.2%Form 10-K (filed 2026-02-20) ↗
Q3 2024Sep 30, 2024181+39.2%Form 10-Q (filed 2025-11-04) ↗
Q2 2024Jun 30, 2024218+21.8%Form 10-Q (filed 2025-08-04) ↗
Q1 2024Mar 31, 2024348+11.2%Form 10-Q (filed 2025-05-09) ↗
Q4 2023Dec 31, 2023125-5.3%Form 10-K (filed 2026-02-20) ↗
Q3 2023Sep 30, 2023130+3.2%Form 10-Q (filed 2024-11-04) ↗
Q2 2023Jun 30, 2023179+67.3%Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 2023313+2.3%Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 2022132+2.3%Form 10-K (filed 2025-02-14) ↗
Q3 2022Sep 30, 2022126-6.7%Form 10-Q (filed 2023-11-06) ↗

Cite this data

StockData. (2026). AbbVie Stock-Based Compensation Expense ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/cap_sbc_exp

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.